CT-0525
1 product
1 abstract
Abstract
A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.Org: Division of Hematology/Oncology, University of Cincinnati Cancer Center,
Product
CT-0525